GR ligands: can we improve the established drugs?
Rehwinkel
Hartmut
H
Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany. hartmut.rehwinkel@schering.de
Schäcke
Heike
H
D000085:Acetates / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D008024:Ligands; D051379:Mice; D011965:Receptors, Glucocorticoid / Q000737:chemistry / Q000187:drug effects*; D014439:Tyramine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
D000085:Acetates; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D008024:Ligands; C514098:N-methyl-2-(4-acetoxyphenyl)-2-chloroethanamine; D011965:Receptors, Glucocorticoid; D014439:Tyramine